Trodelvy戈沙妥珠单抗 sacituzumab govitecan

Drug Class

Trop-2-directed antibody-drug conjugate

Mechanism

An antibody-drug conjugate (ADC) targeting Trop-2, delivering the topoisomerase I inhibitor SN-38 to induce DNA damage and tumor cell death.

Approved Indication

Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, or pretreated HR-positive, HER2-negative metastatic breast cancer.

What This Means For Patients

Trodelvy戈沙妥珠单抗 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2020) — Sources
• EMA — Approved (2021) — Sources
• NMPA — Approved (2022) — Sources

Pivotal Clinical Evidence

• ASCENT — Bardia et al., N Engl J Med 2021 (NCT02574455) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy
• https://www.nmpa.gov.cn/